Search

Displaying results 1741 - 1750 of 6074 in total
  1. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of … [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555]

  3. Drug

    Voacamine

    go.drugbank.com/drugs/DB04877
    Experimental

    It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.

  4. Drug

    Famotidine

    go.drugbank.com/drugs/DB00927
    ApprovedInvestigational

    [L11166] While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.[L11142]

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  5. Drug

    Propanoic acid

    go.drugbank.com/drugs/DB03766
    ApprovedInvestigationalVet approvedWithdrawn

    It is considered generally recognized as safe (GRAS) food ingredient by FDA, where it acts as an antimicrobial agent for food preservation and flavoring agent.

  6. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] Standard therapy for cTTP involves prophylactic plasma infusions to supplement insufficient ADAMTS13 plasma levels. … [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP.

  7. Drug

    Hypochlorite

    go.drugbank.com/drugs/DB11123
    ApprovedInvestigational

    Hypochlorite is often used as a chemical reagent for chlorination and oxidation reactions. … Being unstable in the pure form, hypochlorite is most commonly used for bleaching, disinfectation, and water treatment purposes in its salt form, sodium hypochlorite.

  8. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  9. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. … [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis.

  10. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. … Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C).